Meeting
2023 ASCO Annual Meeting
Reduction in Curie score in neuroblastoma patients treated with naxitamab.
Authors
Jaume Mora
Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu, Barcelona, Spain
Jaume Mora , Godfrey Chi-Fung Chan , Daniel A. Morgenstern , Loredana Amoroso , Karsten Nysom , Joerg Faber , Arthur Wingerter , Melissa Bear , Alba Rubio-San-Simón , Brian H. Kushner , Karen Tornøe , Rene DePont Christensen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT03363373
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 10042)
DOI
10.1200/JCO.2023.41.16_suppl.10042
Abstract #
10042
Poster Bd #
348
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Efficacy of naxitamab in patients with refractory/relapse (R/R) high-risk neuroblastoma (HR-NB) by bone/bone marrow (BM) evaluation, potential sites of residual disease.
First Author: Brian H. Kushner
Poster
2013 ASCO Annual Meeting
Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis.
First Author: Sundar Jagannath
Poster
2024 ASCO Annual Meeting
Safety and efficacy of olutasidenib treatment in elderly patients with relapsed/refractory mIDH1 acute myeloid leukemia.
First Author: Stéphane De Botton
Poster
2023 ASCO Annual Meeting
Efficacy and safety of lurbinectedin in elderly patients with relapsed SCLC.
First Author: Sophie Cousin